Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Change in Accured Expenses (2016 - 2021)

Historic Change in Accured Expenses for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2022 value amounting to -$3.2 million.

  • RedHill Biopharma's Change in Accured Expenses fell 115177.99% to -$3.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$1.2 million, marking a year-over-year increase of 6214.69%. This contributed to the annual value of $3.0 million for FY2024, which is 12277.97% up from last year.
  • According to the latest figures from Q4 2022, RedHill Biopharma's Change in Accured Expenses is -$3.2 million, which was down 115177.99% from $987000.0 recorded in Q3 2022.
  • Over the past 5 years, RedHill Biopharma's Change in Accured Expenses peaked at $17.8 million during Q2 2020, and registered a low of -$4.7 million during Q3 2020.
  • Over the past 5 years, RedHill Biopharma's median Change in Accured Expenses value was $213000.0 (recorded in 2018), while the average stood at $732400.0.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 335897.44% in 2019, then skyrocketed by 644736.84% in 2020.
  • RedHill Biopharma's Change in Accured Expenses (Quarter) stood at $117000.0 in 2018, then tumbled by 3358.97% to -$3.8 million in 2019, then skyrocketed by 149.78% to $1.9 million in 2020, then tumbled by 83.72% to $309000.0 in 2021, then plummeted by 1151.78% to -$3.2 million in 2022.
  • Its Change in Accured Expenses was -$3.2 million in Q4 2022, compared to $987000.0 in Q3 2022 and -$2.2 million in Q2 2022.